Annexin Pharmaceuticals AB Stock
Stocks
ANNX
SE0025159387
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.95 SEK | -0.38% |
|
+0.39% | -34.60% |
| 07-16 | Calendar, Thursday, July 16 | FW |
| 06-23 | Annexin Pharmaceuticals AB Updates On Continuous Promising Data From The Nexus Study Demonstrating Improvement Of Retinal Perfusion In Both Dr And Rvo | CI |
| Market Cap | 91.42M 9.48M 8.29M 7.65M 7.05M 13.29M 913M 13.58M 35.96M 447M 35.62M 34.84M 1.54B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 91.42M 9.48M 8.29M 7.65M 7.05M 13.29M 913M 13.58M 35.96M 447M 35.62M 34.84M 1.54B | EV / Sales 2026 * |
1.21x | EV / Sales 2027 * | - |
| Free-Float |
42.81% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -0.38% | ||
| 1 week | +0.39% | ||
| Current month | +7.47% | ||
| 1 month | +6.58% | ||
| 3 months | -12.79% | ||
| 6 months | -27.65% | ||
| Current year | -34.60% |
| 1 week | 12.65 |  | 13.25 |
| 1 month | 11.9 | | 13.25 |
| Current year | 11.05 | | 23.6 |
| 1 year | 11.05 | | 35.8 |
| 3 years | 11.05 | | 99.8 |
| 5 years | 11.05 | | 225 |
| 10 years | 11.05 | | 1,320 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 01/01/2019 | |
Anna Frostegård
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/01/2016 |
| Director of Finance/CFO | 55 | 11/04/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 50 | 01/01/2017 | |
| Director/Board Member | 73 | - | |
Jan Nilsson
CHM | Chairman | 77 | 01/01/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.38% | +0.39% | -58.76% | -85.89% | 9.48M | |
| +0.24% | -1.54% | +52.85% | +71.85% | 53.83B | |
| -7.17% | -4.39% | +42.72% | +73.32% | 52.1B | |
| +0.80% | -6.31% | +5.62% | +417.78% | 23.48B | |
| -0.09% | -0.01% | -16.85% | -15.41% | 23.13B | |
| -5.95% | -2.58% | +29.53% | -9.47% | 19.36B | |
| -1.14% | +0.03% | +31.67% | -30.65% | 17.56B | |
| -5.16% | -7.00% | +168.44% | +314.96% | 15.2B | |
| -6.91% | -5.83% | +25.17% | +644.30% | 14.83B | |
| +0.43% | -1.03% | +25.75% | +189.74% | 14.06B | |
| Average | -2.53% | -2.32% | +30.61% | +157.05% | 23.36B | |
| Weighted average by Cap. | -2.80% | -2.36% | +39.54% | +143.12% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 75.6M 7.84M 6.85M 6.33M 5.83M 10.99M 755M 11.23M 29.74M 370M 29.46M 28.81M 1.27B | - |
| Net income | 19.6M 2.03M 1.78M 1.64M 1.51M 2.85M 196M 2.91M 7.71M 95.91M 7.64M 7.47M 330M | -58M -6.02M -5.26M -4.85M -4.47M -8.43M -579M -8.62M -22.81M -284M -22.6M -22.1M -977M |
| Net Debt | - | - |
Employees
4
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/07/26 | SEK 12.95 | -0.38% | 178 |
| 16/07/26 | SEK 13.00 | +0.39% | 264 |
| 15/07/26 | SEK 12.95 | +2.37% | 1,063 |
| 14/07/26 | SEK 12.65 | -1.56% | 7,107 |
| 13/07/26 | SEK 12.85 | -0.39% | 2,149 |
Net sales - Rate of surprise
- Stock Market
- Stocks
- ANNX Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
